At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Apr 21, 2026 at 16:05 ET
Foghorn Therapeutics presented new preclinical data at AACR 2026 showing complete and durable tumor regression with its SMARCA2 inhibitor FHD-909 in combination with anti-PD-1, along with promising results from its selective CBP, EP300, and ARID1B degrader programs across multiple cancer models. The data reinforce the potential of its chromatin-targeting pipeline, particularly in difficult-to-treat solid and hematologic malignancies.
- FHD-909 (in collaboration with Lilly) showed complete tumor regression and anti-tumor immune memory in syngeneic mouse models when combined with anti-PD-1 antibody.
- Selective EP300 degrader outperformed clinical benchmark inobrodib in multiple myeloma models, including in pomalidomide-resistant cases.
- FHT-171, a selective CBP degrader, demonstrated strong anti-tumor activity and favorable tolerability in ER+ breast cancer PDX models.
- Robust degradation achieved with cereblon-based selective ARID1B degraders, with potential for oral bioavailability.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access